Dataset Information

Identifying differentially coexpressed module during HIV disease progression: A multiobjective approach.

ABSTRACT: Microarray analysis based on gene coexpression is widely used to investigate the coregulation pattern of a group (or cluster) of genes in a specific phenotype condition. Recent approaches go one step beyond and look for differential coexpression pattern, wherein there exists a significant difference in coexpression pattern between two phenotype conditions. These changes of coexpression patterns generally arise due to significant change in regulatory mechanism across different conditions governed by natural progression of diseases. Here we develop a novel multiobjective framework DiffCoMO, to identify differentially coexpressed modules that capture altered coexpression in gene modules across different stages of HIV-1 progression. The objectives are built to emphasize the distance between coexpression pattern of two phenotype stages. The proposed method is assessed by comparing with some state-of-the-art techniques. We show that DiffCoMO outperforms the state-of-the-art for detecting differential coexpressed modules. Moreover, we have compared the performance of all the methods using simulated data. The biological significance of the discovered modules is also investigated using GO and pathway enrichment analysis. Additionally, miRNA enrichment analysis is carried out to identify TF to miRNA and miRNA to TF connections. The gene modules discovered by DiffCoMO manifest regulation by miRNA-28, miRNA-29 and miRNA-125 families.

SUBMITTER: Ray S

PROVIDER: S-EPMC5428367 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Identifying differentially coexpressed module during HIV disease progression: A multiobjective approach.

Ray Sumanta S Maulik Ujjwal U

Scientific reports 20170307 1

Microarray analysis based on gene coexpression is widely used to investigate the coregulation pattern of a group (or cluster) of genes in a specific phenotype condition. Recent approaches go one step beyond and look for differential coexpression pattern, wherein there exists a significant difference in coexpression pattern between two phenotype conditions. These changes of coexpression patterns generally arise due to significant change in regulatory mechanism across different conditions governed ...[more]

PMID: 28273892

Similar Datasets

Project description:BackgroundLittle is known regarding HIV disease outcomes among individuals who become infected with HIV while receiving antiretroviral medications for prevention. We compared HIV disease parameters among women who seroconverted while receiving tenofovir-containing oral or vaginal pre-exposure prophylaxis (PrEP) to placebo.MethodsParticipants with HIV seroconversion in a randomized placebo-controlled trial of oral tenofovir, oral tenofovir/emtricitabine, and vaginal tenofovir gel (MTN-003) were followed in a longitudinal cohort study (MTN-015). The effect of oral and vaginal tenofovir-containing PrEP on HIV disease progression was compared to placebo using linear mixed effects and Cox proportional hazard models, as appropriate. Additional analyses were performed to compare the outcomes among participants with detectable tenofovir or emtricitabine in plasma at the first quarterly visit in MTN-003.ResultsA total of 224 participants were included in the analysis; 93% from South Africa and 94% clade C virus. No differences in HIV RNA at steady state or the trajectory over 12 months were observed for each active arm compared to placebo; tenofovir gel recipients had higher CD4+ T cell counts (722 vs 596 cells/mm3; p = 0.02) at 90 days after estimated HIV seroconversion and higher average rates of change over 12 months compared to placebo (-181 vs -92 cells/mm3 per year; p = 0.08). With a median follow-up of 31 months, no significant differences were observed for time to CD4+ T cell count ≤350 cells/mm3, or the composite endpoint of CD4+ T cells ≤350 cells/mm3, initiation of antiretroviral therapy or death for each active arm compared to placebo. Additionally, there were no significant differences in the HIV RNA or CD4+ T cell counts at baseline, the change to month 12, or any disease progression outcomes among participants with oral drug detected and no oral drug detected compared to placebo.ConclusionsNo clinically significant differences in HIV seroconversion outcomes were observed among women randomized to tenofovir-containing oral or vaginal PrEP regimens, however low overall adherence limits the generalizability of these findings.

Dataset Information

Identifying differentially coexpressed module during HIV disease progression: A multiobjective approach.

Publications

Identifying differentially coexpressed module during HIV disease progression: A multiobjective approach.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets